Academic Journal
Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial
| العنوان: | Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial |
|---|---|
| المؤلفون: | Schechter, Meir, Wiviott, Stephen D., Raz, Itamar, Goodrich, Erica L., Rozenberg, Aliza, Yanuv, Ilan, Murphy, Sabina, Zelniker, Thomas A., Fredriksson, Martin, Johansson, Peter A, Leiter, Lawrence A., Bhatt, Deepak, McGuire, Darren K, Wilding, John P. H., Gause-Nilson, Ingrid A. M., Cahn, Avivit, Langkilde, Anna Maria, Sabatine, Marc S., Mosenzon, Ofri |
| المصدر: | Schechter , M , Wiviott , S D , Raz , I , Goodrich , E L , Rozenberg , A , Yanuv , I , Murphy , S , Zelniker , T A , Fredriksson , M , Johansson , P A , Leiter , L A , Bhatt , D , McGuire , D K , Wilding , J P H , Gause-Nilson , I A M , Cahn , A , Langkilde , A M , Sabatine , M S & Mosenzon , O 2023 , ' Effects of dapagliflozin on hospitalisations in people with type .... |
| سنة النشر: | 2023 |
| المجموعة: | University of Groningen research database |
| الوصف: | Background In people with type 2 diabetes at high risk of cardiovascular or kidney disease, sodium-glucose co-transporter 2 (SGLT2) inhibitors consistently reduce the risk of hospitalisations for heart failure. Less is known about their effects on hospitalisation from any cause, especially in people with type 2 diabetes without atherosclerotic cardiovascular disease, which includes most of the global population of people with type 2 diabetes. We aimed to assess the effect of the SGLT2 inhibitor, dapagliflozin, on the risks of hospitalisations for any cause and for specific causes in people with type 2 diabetes with and without atherosclerotic cardiovascular disease. Methods The DECLARE-TIMI 58 trial was a double-blind, multicentre, randomised, placebo-controlled study. People with type 2 diabetes and either risk factors for or established atherosclerotic cardiovascular disease were randomly assigned (1:1) to receive oral dapagliflozin 10 mg or placebo once daily. In these post-hoc analyses, the effects of dapagliflozin on risks of first non-elective any-cause and cause-specific hospitalisation were assessed with Cox proportional hazards regression models overall and in the subset of participants without prevalent atherosclerotic cardiovascular disease. The risk of total (first plus subsequent) non-elective hospitalisations was assessed with Lin-Wei-Ying-Yang model. Investigator-reported System Organ Class terms were used to classify cause-specific hospitalisations. The trial is registered with ClinicalTrials.gov, NCT01730534. Findings Between April 25, 2013, and Sept 18, 2018, 17 160 people (6422 [37·4%] women, 10 738 [62·6%] men; mean age 63·9 years [SD 6·8]) were enrolled in the original trial, of whom 10186 (59·4%) had multiple risk factors for but did not have established atherosclerotic cardiovascular disease, and 6835 (39·8%) had both no evidence of atherosclerotic cardiovascular disease and low KDIGO risk. Over a median follow-up of 4·2 years (IQR 3·9–4·4), dapagliflozin was associated with a lower risk ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| DOI: | 10.1016/S2213-8587(23)00009-8 |
| الاتاحة: | https://hdl.handle.net/11370/b7f5de5d-93e3-4e6b-9731-c235ff5e4406 https://research.rug.nl/en/publications/b7f5de5d-93e3-4e6b-9731-c235ff5e4406 https://doi.org/10.1016/S2213-8587(23)00009-8 https://pure.rug.nl/ws/files/672273139/1_s2.0_S2213858723000098_main.pdf |
| Rights: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.EF8F9C23 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/S2213-8587(23)00009-8 |
|---|